| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
TB5 is a novel, potent, selective, reversible and competitive inhibitor of hMAO-B (human monoamine oxidase-B) with Ki value of 0.11±0.01 μM. TB5 is can be potentially used for the treatment of neurodegenerative disorders like PD and AD (Parkinson's and Alzheimer's diseases). In addition, TB5 was found to be nontoxic at 5 and 25 μm, with 95.75% and 84.59 % viability among cells, respectively.
| ln Vitro |
hMAO-B and hMAO-A's catalytic sites interact with TB5 and TB8 through a competitive method of inhibition. With Ki and SI values of 0.11±0.01μM and 13.18, compound TB5 exhibits the highest selectivity and best inhibitory action toward hMAO-B. After 24 hours of dialysis, the inhibition of hMAO-A by compound TB8 and hMAO-B by compound TB5 is totally reversed. According to cytotoxicity experiments, TB5 has no hazardous effects at 5 and 25 μM, meaning that 95.75% and 84.59% of cells can survive, respectively. [1].
|
||
|---|---|---|---|
| ln Vivo |
The compounds are diluted with PBS/EtOH (70:30) after being dissolved in DMSO (5 mg/mL). We do kinetic analyses on TB5 and TB8. A series of Lineweaver–Burk plots was created with and without different amounts of the chemicals TC8 and TB5. Each of the five graphs in the collection was created by calculating the catalytic rates of MAO-B and MAO-A at various substrate concentrations (0.1–1 μM). While the remaining four graphs are created with varying amounts of TB5 and TB8, the first Lineweaver–Burk plot is created without an inhibitor[1].
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C15H14BRNOS
|
|
|---|---|---|
| Molecular Weight |
336.25
|
|
| Exact Mass |
334.998
|
|
| CAS # |
948841-07-4
|
|
| Related CAS # |
|
|
| PubChem CID |
101571768
|
|
| Appearance |
White to yellow solid powder
|
|
| LogP |
4.9
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
19
|
|
| Complexity |
337
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CN(C)C1=CC=C(C=C1)/C=C/C(=O)C2=CC=C(S2)Br
|
|
| InChi Key |
PTLDLBSWTKNYCY-VMPITWQZSA-N
|
|
| InChi Code |
InChI=1S/C15H14BrNOS/c1-17(2)12-6-3-11(4-7-12)5-8-13(18)14-9-10-15(16)19-14/h3-10H,1-2H3/b8-5+
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9740 mL | 14.8699 mL | 29.7398 mL | |
| 5 mM | 0.5948 mL | 2.9740 mL | 5.9480 mL | |
| 10 mM | 0.2974 mL | 1.4870 mL | 2.9740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05402748 | Recruiting | Other: placenta-MSCs derived exosomes |
Fistula Perianal | Tehran University of Medical Sciences |
December 22, 2021 | Phase 1 Phase 2 |
| NCT05499156 | Unknown | Other: placenal MSC derived exosomes |
Perianal Fistula in Patients With Crohn's Disease |
Tehran University of Medical Sciences |
January 20, 2022 | Phase 1 Phase 2 |
| NCT00628758 | Completed | Drug: Symbicort TBH - Turbuhaler Drug: beta-II-agonist, inhale steroid |
Asthma | AstraZeneca | December 2005 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
